Table 1

Demographic and baseline characteristics in imaging population, categorised by palpable tophus status and sUA level

VariableTophus statussUATotal
Presence
(n=48)
Absence
(n=105)
≥6.0 mg/dL
(n=75)
<6.0 mg/dL
(n=78)
(n=153)
Age (years), mean (SD)58.0 (11.06)58.7 (11.63)55.9 (10.98)60.9 (11.36)58.5 (11.42)
Male, n (%)48 (100)93 (88.6)71 (94.7)70 (89.7)141 (92.2)
Race, n (%)
 White28 (58.3)71 (67.6)44 (58.7)55 (70.5)99 (64.7)
 Non-white20 (41.7)34 (32.4)31 (41.3)23 (29.5)54 (35.3)
Duration since gout diagnosis (years), mean (SD)18.30 (11.60)13.39 (9.28)14.72 (9.69)15.13 (10.89)14.93 (10.29)
≥1 gout flares in past 12 months, n (%)28 (58.3)54 (51.4)51 (68.0)31 (39.7)82 (53.6)
Total allopurinol daily dose, n (%)
 300 mg30 (62.5)95 (90.5)64 (85.3)61 (78.2)125 (81.7)
 >300 mg18 (37.5)10 (9.5)11 (14.7)17 (21.8)28 (18.3)
Duration of allopurinol treatment (years), mean (SD)3.43 (4.64)5.80 (7.58)4.86 (6.75)5.24 (7.02)5.05 (6.87)
Day 1 sUA level, mean (SD)
 <6.0 mg/dL28 (58.3)50 (47.6)N/A78 (100)78 (51.0)
 ≥6.0 mg/dL20 (41.7)55 (52.4)75 (100)N/A75 (49.0)
  • sUA, serum urate.